Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritis.

One decade ago, James Rudd, who also coauthored the present article, published the results of the first prospective trial investigating 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) for imaging of inflammatory changes in carotid artery disease in Circulation. 1 Since that time, FDG-PET has emerged as a powerful noninvasive technique to measure vascular inflammation due to atherosclerosis.1–10 Article see p 2473 The FDG uptake in the inflamed arterial wall or in inflamed vascular plaques is thought to depict macrophage activity, which by itself might be driven by hypoxia.11–13 Over time, several prospective and retrospective studies evaluated the diagnostic impact of vascular FDG-PET not only in the clinical, but also in the animal setting. Today, there is emerging evidence indicating that noninvasive PET imaging shows a significant correlation with established clinical cardiovascular risk factors such as obesity, smoking, older age, male sex, hypercholesterolemia, Framingham risk score, diabetes mellitus, insulin resistance, C-reactive protein, and matrix metalloproteinases, and plaque high-risk morphological features.14–19 Furthermore, it was also shown that FDG-PET is able to serve as a predictive marker for emerging cardiovascular events.20 Most interestingly, inflammatory vascular …

[1]  J. H. Rudd,et al.  Anti-Tumor Necrosis Factor-&agr; Therapy Reduces Aortic Inflammation and Stiffness in Patients With Rheumatoid Arthritis , 2012, Circulation.

[2]  Jeffrey R Curtis,et al.  A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. , 2012, Arthritis and rheumatism.

[3]  S. Abbara,et al.  Arterial inflammation in patients with HIV. , 2012, JAMA.

[4]  Zahi A Fayad,et al.  Impact of noninsulin-dependent type 2 diabetes on carotid wall 18F-fluorodeoxyglucose positron emission tomography uptake. , 2012, Journal of the American College of Cardiology.

[5]  Sungeun Kim,et al.  Association between sRAGE, esRAGE levels and vascular inflammation: analysis with (18)F-fluorodeoxyglucose positron emission tomography. , 2012, Atherosclerosis.

[6]  R. Cury,et al.  Distribution of Inflammation Within Carotid Atherosclerotic Plaques With High-Risk Morphological Features: A Comparison Between Positron Emission Tomography Activity, Plaque Morphology, and Histopathology , 2012, Circulation. Cardiovascular imaging.

[7]  Claudia Calcagno,et al.  Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. , 2011, JACC. Cardiovascular imaging.

[8]  Ahmed Tawakol,et al.  Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial , 2011, The Lancet.

[9]  P. Libby,et al.  Hypoxia but not inflammation augments glucose uptake in human macrophages: Implications for imaging atherosclerosis with 18fluorine-labeled 2-deoxy-D-glucose positron emission tomography. , 2011, Journal of the American College of Cardiology.

[10]  V. Fuster,et al.  Rationale and design of dal-PLAQUE: a study assessing efficacy and safety of dalcetrapib on progression or regression of atherosclerosis using magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography/computed tomography. , 2011, American heart journal.

[11]  O. Schober,et al.  F-18-FDG Imaging for Atherosclerotic Plaque Characterization , 2011 .

[12]  T. Brady,et al.  Positron emission tomography measurement of periodontal 18F-fluorodeoxyglucose uptake is associated with histologically determined carotid plaque inflammation. , 2011, Journal of the American College of Cardiology.

[13]  Ahmed Tawakol,et al.  Feasibility of FDG imaging of the coronary arteries: comparison between acute coronary syndrome and stable angina. , 2010, JACC. Cardiovascular imaging.

[14]  Sungeun Kim,et al.  Vascular Inflammation in Patients With Impaired Glucose Tolerance and Type 2 Diabetes: Analysis With 18F-Fluorodeoxyglucose Positron Emission Tomography , 2010, Circulation. Cardiovascular imaging.

[15]  V. Fuster,et al.  Multimodality imaging of atherosclerotic plaque activity and composition using FDG-PET/CT and MRI in carotid and femoral arteries. , 2009, Atherosclerosis.

[16]  M. Reiser,et al.  18F-FDG PET/CT Identifies Patients at Risk for Future Vascular Events in an Otherwise Asymptomatic Cohort with Neoplastic Disease , 2009, Journal of Nuclear Medicine.

[17]  Sameer Bansilal,et al.  Atherosclerosis Inflammation Imaging with 18F-FDG PET: Carotid, Iliac, and Femoral Uptake Reproducibility, Quantification Methods, and Recommendations , 2008, Journal of Nuclear Medicine.

[18]  V. Fuster,et al.  (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. , 2007, Journal of the American College of Cardiology.

[19]  T. Imaizumi,et al.  Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. , 2007, Journal of the American College of Cardiology.

[20]  Ahmed Tawakol,et al.  In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. , 2006, Journal of the American College of Cardiology.

[21]  Masatoshi Ishibashi,et al.  Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. , 2006, Journal of the American College of Cardiology.

[22]  J. Pickard,et al.  Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography , 2002, Circulation.

[23]  A. Alavi,et al.  F-18 FDG Uptake in the Large Arteries: A New Observation , 2001, Clinical nuclear medicine.

[24]  G. Pinkus,et al.  Rheumatoid Aortitis: A Rarely Recognized but Clinically Significant Entity , 1989, Medicine.

[25]  Z. Fayad,et al.  Correlation between arterial FDG uptake and biomarkers in peripheral artery disease. , 2012, JACC. Cardiovascular imaging.

[26]  M. Farkouh,et al.  Cardiovascular safety of biologic therapies for the treatment of RA , 2012, Nature Reviews Rheumatology.

[27]  A. Alavi,et al.  18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. , 2002, Seminars in nuclear medicine.